Compound: RANOLAZINE
SMILES: O=C(Nc1c(cccc1C)C)CN2CCN(CC(O)COc3c(OC)cccc3)CC2
InChIKey: XKLMZUWKNUAPSZ-UHFFFAOYSA-N
Synonyms: RANOLAZINE, 95635-55-5, Ranexa, CVT-303, RAN D, Ran4, RS-43285-003, (+-)-Ranolazine, ASPRUZYO, Ranolazina, renolazine, NSC-759100, A6IEZ5M406, DTXSID3045196, N-(2,6-DIMETHYLPHENYL)-4-[2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL]-1-PIPERAZINEACETAMIDE, DTXCID1025196, RS43285, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide, 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, ranolazinum, HCl, Ranolazine, N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)ethanimidic acid, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}ethanimidic acid, ASPRUZYO SPRINKLE, RefChem:55969, Hydrochloride, Ranolazine, Dihydrochloride, Ranolazine, CHEBI:87681, C01EB18, 43285, RS, RS 43285193, RS 43285 193, N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide, N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide, 142387-99-3, C24H33N3O4, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide, MFCD00864690, CHEBI:87690, NCGC00015897-02, (-)-Ranolazine, Latixa, CAS-95635-55-5, Ranexa (TN), Ranolazine [USAN], SR-01000076216, Ranolazine (USAN/INN), UNII-A6IEZ5M406, Ranolazin, Ranolazine [USAN:INN:BAN], HSDB 7924, KEG-1295, Ranolazine (Ranexa), (+/-)-Ranolazine, Ranolazine (Ranexa)?, Ranolazine (Standard), RANOLAZINE [MI], RANOLAZINE [INN], GlyTouCan:G17204EU, RANOLAZINE [VANDF], RANOLAZINE [MART.], CHEMBL1404, RANOLAZINE [USP-RS], RANOLAZINE [WHO-DD], Lopac0_001062, BSPBio_002276, MLS002154149, RANOLAZINE [EMA EPAR], SCHEMBL124665, SPECTRUM1505366, GTPL7291, orb1300599, Ranolazine - Bio-X trade mark, SCHEMBL7933344, RANOLAZINE [ORANGE BOOK], HY-B0280R, GLXC-07953, HMS1922F16, HMS2090L09, HMS2093D21, HMS2098K06, HMS2230C19, HMS3369I08, HMS3655M12, HMS3715K06, HMS3884I10, HMS5080E09, Pharmakon1600-01505366, G17204EU, HY-B0280, PEA24680, SFA38799, STB80488, Tox21_110258, BDBM50173335, EBC-11221, NSC759100, NSC782305, s1799, AKOS015889500, Tox21_110258_1, AC-1673, CCG-205139, DB00243, FD61499, KS-1244, NSC 759100, NSC-782305, PB21724, SB13209, SDCCGSBI-0051032.P003, NCGC00015897-03, NCGC00015897-04, NCGC00015897-05, NCGC00015897-06, NCGC00015897-08, NCGC00015897-22, NCGC00095177-01, NCGC00095177-02, NCGC00095177-03, BD164322, SMR000857382, SBI-0051032.P002, NS00002495, SW197620-4, D05700, EN300-122384, AB00698532-11, AB00698532-13, AB00698532-14, AB00698532-15, AB00698532_16, AB00698532_17, AB00698532_18, F079440, Q907104, SR-01000076216-5, SR-01000076216-8, BRD-A97674275-001-01-9, BRD-A97674275-001-04-3, BRD-A97674275-001-10-0, BRD-A97674275-001-11-8, BRD-A97674275-300-03-1, Z68563450, Ranolazine Working Standard (Secondary Reference Standard), (+/-)-4-(2-Hydroxy-3-(o-methoxyphenoxy)propyl)-1-piperazineaceto-2',6'-xylidide, (+-)-N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide, (+/-)-1-(3-(2-Methoxyphenoxy)-2-hydroxypropyl)-4-(n-(2,6-dimethylphenyl)carbamoylmethyl)piperazine, (+/-)-N-(2,6-DIMETHYLPHENYL)-4-(2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL)-1-PIPERAZINEACETAMIDE, 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine, 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, (+-)-, 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/-)-, 1080496-58-7, N-(2,6-Dimethyl-phenyl)-2-{4-[2-hydroxy-3-(2-methoxy-phenoxy)-propyl]-piperazin-1-yl}-acetamide, N-(2,6-DIMETHYLPHENYL)-2-(4-((2RS)-2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL)PIPERAZIN-1-YL)ACETAMIDE, N-(2,6-Dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxy-phenoxy)propyl)piperazin-1-yl)acetamide
Theoretical properties:
molecular_formula: C24H33N3O4
molecular_weight: 427.5 g/mol
exact_mass: 427.24710654 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 9
heavy_atom_count: 31
topological_polar_surface_area: 74.3 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
physical_state: White to off-white solid
color: White to off-white solid
melting_point: 120-124
solubility: <1 mg/ml
Descriptions:
pubchem: N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide is an aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline. It is a monomethoxybenzene, a monocarboxylic acid amide, a secondary alcohol, a N-alkylpiperazine and an aromatic amide.
chebi: An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.
chembl: RANOLAZINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain. Typically it is used together with other medications when those are insufficient. Therapeutic benefits appear smaller in females than males. It is taken by mouth.
Common side effects include constipation, headache, nausea, and dizziness. Serious side effects may include QT prolongation. Ranolazine is contraindicated (not recommended) in those with liver cirrhosis. How it works is not clear but may involve adenosine triphosphate.
Ranolazine was approved for medical use in the United States in 2006. In 2022, it was the 232nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.